TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors-Reference-Cited by-同舟云学术

TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

Published:2019-12-03 Issue:1 Volume:14 Page:54-68
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Gymnopoulos Marco¹^ORCID,Betancourt Oscar¹,Blot Vincent¹,Fujita Ryo¹,Galvan Diana¹,Lieuw Vincent¹,Nguyen Sophie¹,Snedden Jeanette¹,Stewart Christine¹,Villicana Jose¹,Wojciak Jon¹,Wong Eley¹,Pardo Raul²,Patel Neki²,D’Hooge Francois²,Vijayakrishnan Balakumar²,Barry Conor²,Hartley John A.²,Howard Philip W.²,Newman Roland¹,Coronella Julia¹

Affiliation:

1. Tanabe Research Laboratories U.S.A., Inc. San Diego CA USA

2. Spirogen, a member of the AstraZeneca Group London UK

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12600

Reference53 articles.

1. Development of New ADC Technology with Topoisomerase I Inhibitor

2. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib